Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07837362 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer

Name: SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer — clinical trial record (NCT07837362)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorFudan University

Started2026-09-01

View on ClinicalTrials.gov ↗

Fudan University

624 trials monitored

See 9 trials at risk

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

The study evaluates the combination of immunotherapy of PD-1/ CTLA4 antibody and neoadjuvant short-course radiotherapy in early low rectal cancer. A total of 34 patients will receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and PD-1/ CTLA4 antibody, finally receive the local excision(TEM) or total mesorectal excision (TME). The rate of complete response (cCR+pCR), Organ retention rate, long-term prognosis, and adverse effects will be analyzed.

Trial Details

NCT Number	NCT07837362
Lead Sponsor	Fudan University
Conditions	Early Low Rectal Cancer
Enrollment	34 participants
Start Date	2026-09-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-23